* pregnant or lactating females; * unwillingness or inability to complete the study. * rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator; * egfr \< 30 ml/min/m2 assessed with ckd epi formula; * current or chronic history of liver disease (child pugh score ≥ 10), or known hepatic or biliary abnormalities; * participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); * patients requiring high doses of loop diuretics (i.e. \> 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically; * history of allergy; * history of sensitivity to heparin or heparin-induced thrombocytopenia; * unstable hemodynamics in the preceding 4 hours (sbp \< 90 mmhg, and/or vasoactive agents required); * hemoglobin \< 7 at time of drug infusion. transfusion is allowed to increase hemoglobin levels before entry into the study; * malignancy or any other condition for which estimated 6-month mortality \>50%; * arterial blood ph less than 7.2; * known evidence of chronic interstitial infiltration at imaging; * known hospitalization within the past six months for respiratory failure (paco2 \> 50 mmhg or pao2 \< 55 mmhg, or oxygen saturation \<88% on fio2 = 0.21); * known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties); * known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency; * known vasculitis with diffuse alveolar hemorrhage;. * pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy; * extracorporeal membrane oxygenation (ecmo); * immunosuppressive treatment; * patient in trials for covid-19 within 30 days before; * unstable hemodynamics in the preceding 4 hours (map ≤ 65 mmhg, or sap \< 90 mmhg, dap \< 60 mmhg, and vasoactive agents required); * hyperkalemia , i.e. serum k+ levels \> 5.0 meq/l; * severe active bleeding; * any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.

* pregnant or lactating females; * unwillingness or inability to complete the study. * rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator; * egfr \< 30 ml/min/m2 assessed with ckd epi formula; * current or chronic history of liver disease (child pugh score ≥ 10), or known hepatic or biliary abnormalities; * participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); * patients requiring high doses of loop diuretics (i.e. \> 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically; * history of allergy; * history of sensitivity to heparin or heparin-induced thrombocytopenia; * unstable hemodynamics in the preceding 4 hours (sbp \< 90 mmhg, and/or vasoactive agents required); * hemoglobin \< 7 at time of drug infusion. transfusion is allowed to increase hemoglobin levels before entry into the study; * malignancy or any other condition for which estimated 6-month mortality \>50%; * arterial blood ph less than 7.2; * known evidence of chronic interstitial infiltration at imaging; * known hospitalization within the past six months for respiratory failure (paco2 \> 50 mmhg or pao2 \< 55 mmhg, or oxygen saturation \<88% on fio2 = 0.21); * known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties); * known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency; * known vasculitis with diffuse alveolar hemorrhage;. * pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy; * extracorporeal membrane oxygenation (ecmo); * immunosuppressive treatment; * patient in trials for covid-19 within 30 days before; * unstable hemodynamics in the preceding 4 hours (map ≤ 65 mmhg, or sap \< 90 mmhg, dap \< 60 mmhg, and vasoactive agents required); * hyperkalemia , i.e. serum k+ levels \> 5.0 meq/l; * severe active bleeding; * any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.

- pregnant or lactating females; - unwillingness or inability to complete the study. - rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator; - egfr < 30 ml/min/m2 assessed with ckd epi formula; - current or chronic history of liver disease (child pugh score ≥ 10), or known hepatic or biliary abnormalities; - participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); - patients requiring high doses of loop diuretics (i.e. > 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically; - history of allergy; - history of sensitivity to heparin or heparin-induced thrombocytopenia; - unstable hemodynamics in the preceding 4 hours (sbp < 90 mmhg, and/or vasoactive agents required); - hemoglobin < 7 at time of drug infusion. transfusion is allowed to increase hemoglobin levels before entry into the study; - malignancy or any other condition for which estimated 6-month mortality >50%; - arterial blood ph less than 7.2; - known evidence of chronic interstitial infiltration at imaging; - known hospitalization within the past six months for respiratory failure (paco2 > 50 mmhg or pao2 < 55 mmhg, or oxygen saturation <88% on fio2 = 0.21); - known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties); - known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency; - known vasculitis with diffuse alveolar hemorrhage;. - pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy; - extracorporeal membrane oxygenation (ecmo); - immunosuppressive treatment; - patient in trials for covid-19 within 30 days before; - unstable hemodynamics in the preceding 4 hours (map ≤ 65 mmhg, or sap < 90 mmhg, dap < 60 mmhg, and vasoactive agents required); - hyperkalemia , i.e. serum k+ levels > 5.0 meq/l; - severe active bleeding; - any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.

- pregnant or lactating females; - unwillingness or inability to complete the study. - rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator; - egfr < 30 ml/min/m2 assessed with ckd epi formula; - current or chronic history of liver disease (child pugh score ≥ 10), or known hepatic or biliary abnormalities; - participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); - patients requiring high doses of loop diuretics (i.e. > 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically; - history of allergy; - history of sensitivity to heparin or heparin-induced thrombocytopenia; - unstable hemodynamics in the preceding 4 hours (sbp < 90 mmhg, and/or vasoactive agents required); - hemoglobin < 7 at time of drug infusion. transfusion is allowed to increase hemoglobin levels before entry into the study; - malignancy or any other condition for which estimated 6-month mortality >50%; - arterial blood ph less than 7.2; - known evidence of chronic interstitial infiltration at imaging; - known hospitalization within the past six months for respiratory failure (paco2 > 50 mmhg or pao2 < 55 mmhg, or oxygen saturation <88% on fio2 = 0.21); - known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties); - known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency; - known vasculitis with diffuse alveolar hemorrhage;. - pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy; - extracorporeal membrane oxygenation (ecmo); - immunosuppressive treatment; - patient in trials for covid-19 within 30 days before; - unstable hemodynamics in the preceding 4 hours (map ≤ 65 mmhg, or sap < 90 mmhg, dap < 60 mmhg, and vasoactive agents required); - hyperkalemia , i.e. serum k+ levels > 5.0 meq/l; - severe active bleeding; - any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.